Published in Cancer Gene Ther on April 01, 2006
Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) (2011) 2.31
The molecular pathogenesis of osteosarcoma: a review. Sarcoma (2011) 1.91
Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release (2013) 1.08
Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer (2013) 0.94
Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone (2006) 0.87
Adenovirally mediated p53 overexpression diversely influence the cell cycle of HEp-2 and CAL 27 cell lines upon cisplatin and methotrexate treatment. J Cancer Res Clin Oncol (2009) 0.81
p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. Cancer Chemother Pharmacol (2015) 0.78
Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition. J Exp Clin Cancer Res (2017) 0.75
[The use of p53 as a tool for human cancer therapy]. Mol Biol (Mosk) (2008) 0.75
Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies. Biomolecules (2017) 0.75
Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA. Int J Nanomedicine (2017) 0.75
Synergistic effect of bladder cancer-specific oncolytic adenovirus in combination with chemotherapy. Oncol Lett (2017) 0.75
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
Profound block in thymocyte development in mice lacking p56lck. Nature (1992) 5.48
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet (1996) 3.08
Diffusion tensor imaging of white matter tract evolution over the lifespan. Neuroimage (2011) 2.92
Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet (1996) 2.32
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev (2001) 1.95
Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril (1997) 1.93
Induction of increased calcium uptake in mouse T lymphocytes by concanavalin A and its modulation by cyclic nucleotides. Nature (1975) 1.82
Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant (2003) 1.80
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A (1991) 1.65
Nocturnal cortisol, thyroid stimulating hormone, and growth hormone secretory profiles in depressed adolescents. J Am Acad Child Adolesc Psychiatry (1991) 1.60
A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science (1989) 1.60
Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child (1989) 1.59
Expression and purification of the Saccharomyces cerevisiae alpha-factor receptor (Ste2p), a 7-transmembrane-segment G protein-coupled receptor. J Biol Chem (1997) 1.56
Screening for germ line TP53 mutations in breast cancer patients. Cancer Res (1992) 1.55
An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ (2000) 1.54
Phylogenetic analysis of the mitochondrial genome indicates significant differences between patients with Alzheimer disease and controls in a French-Canadian founder population. Am J Med Genet (1999) 1.49
Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol (1990) 1.45
Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood (1994) 1.45
Shwachman-Diamond syndrome: An inherited preleukemic bone marrow failure disorder with aberrant hematopoietic progenitors and faulty marrow microenvironment. Blood (1999) 1.45
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest (1995) 1.43
Long-term follow-up of weight status of subjects in a behavioral weight control program. J Am Diet Assoc (1989) 1.42
Alternative donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol (2000) 1.42
Thrombocytopenia with absent radii: frequency of marrow megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. Pediatr Hematol Oncol (2000) 1.40
Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med (1987) 1.39
Determination of the tautomeric form of the imidazole ring of L-histidine in basic solution by carbon-13 magnetic resonance spectroscopy. J Am Chem Soc (1973) 1.37
Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood (1984) 1.36
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res (2001) 1.33
High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst (1994) 1.33
Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. Eur J Immunol (1994) 1.32
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med (1985) 1.30
Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol (2000) 1.30
Soluble antigen-antibody complexes as intermediates in the purification of antibodies in 8 molar urea. Arch Biochem Biophys (1966) 1.30
Visual working memory in primary generalized epilepsy: an 18FDG-PET study. Neurology (1996) 1.26
Carbon-13 nuclear magnetic resonance titration shifts in amino acids. J Am Chem Soc (1974) 1.26
Shwachman syndrome: exocrine pancreatic dysfunction and variable phenotypic expression. Gastroenterology (1996) 1.25
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene (1994) 1.25
Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol (1996) 1.24
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood (1999) 1.24
Immune function in patients with Shwachman-Diamond syndrome. Br J Haematol (2001) 1.21
Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am (1998) 1.21
The effects of complete modification of amino groups on the antibody activity of antihapten antibodies. Reversible inactivation with maleic anhydride. Biochemistry (1968) 1.19
High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet (2009) 1.19
Genetic predisposition to cancer and familial cancer syndromes. Pediatr Clin North Am (1997) 1.17
Mutations of the p53 gene do not occur in testis cancer. Cancer Res (1993) 1.17
Assisted hatching in the treatment of poor prognosis in vitro fertilization candidates. Fertil Steril (1994) 1.14
Systemic vasculitis following influenza vaccination--report of 3 cases and literature review. J Rheumatol (1993) 1.13
In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood (1987) 1.13
Differences in susceptibility of human cells to mouse sarcoma virus. J Natl Cancer Inst (1971) 1.11
Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. Am J Pathol (1996) 1.09
Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet (1995) 1.08
Diamond-blackfan anemia: etiology, pathophysiology, and treatment. Am J Pediatr Hematol Oncol (1989) 1.06
Fanconi's anaemia and pregnancy. Br J Haematol (1991) 1.05
The morbidity and mortality of splenectomy in childhood. Ann Surg (1977) 1.04
Shwachman-Diamond syndrome marrow cells show abnormally increased apoptosis mediated through the Fas pathway. Blood (2001) 1.04
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet (1990) 1.03
Hypoxia induces capillary network formation in cultured bovine pulmonary microvessel endothelial cells. Am J Physiol (1995) 1.03
Autoerythrocyte sensitization. J Pediatr (1983) 1.02
The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood (1996) 1.01
Effect of altitude exposure on platelets. J Appl Physiol (1975) 1.01
Early biochemical events in lymphocyte activation. I. Investigations on the nature and significance of early calcium fluxes observed in mitogen-induced T and B lymphocytes. Cell Immunol (1979) 1.01
Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci (1995) 1.01
Drug use prevention programs, gender, and ethnicity: evaluation of three seventh-grade Project SMART cohorts. Prev Med (1990) 1.01
The use of preparative liquid isoelectric focusing for the further purification of rabbit antihapten antibodies. J Immunol Methods (1972) 1.00
Rat liver daunorubicin reductase. An aldo-keto reductase. J Biol Chem (1974) 0.99
Carbon-13 nuclear-magnetic-resonance studies on selected amino acids, peptides, and proteins. Eur J Biochem (1973) 0.99
Cortical metabolic activation in humans during a visual memory task. Cereb Cortex (1995) 0.99
Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol (2001) 0.98
A family outbreak of hemolytic-uremic syndrome associated with verotoxin-producing Escherichia coli serotype O157:H7. Pediatr Nephrol (1988) 0.97
Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest (1986) 0.96
The effect of prostacyclin infusion on endotoxin-induced lung injury. Surgery (1981) 0.96
Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant (1995) 0.96
Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med (1990) 0.96
p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene (1999) 0.96
Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand (2012) 0.95
Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene (2008) 0.95
More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers (1999) 0.95
Management of intracerebral hemorrhage in idiopathic thrombocytopenic purpura. Report of four cases. J Neurosurg (1976) 0.95
Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. J Exp Med (1999) 0.95
Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood (1991) 0.95
Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line. Leuk Res (1992) 0.94
Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol (1992) 0.94
Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood (1996) 0.94
Fatal peri-operative acute tumour lysis syndrome precipitated by dexamethasone. Anaesthesia (2008) 0.94
A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr Res (2003) 0.94
Transient erythroblastopenia of childhood: varied pathogenesis. Am J Hematol (1983) 0.94
Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood (1986) 0.93
Congenital bronchobiliary fistula: diagnosis and postoperative surveillance with HIDA scan. J Pediatr Surg (1996) 0.93
Hematopoiesis in the human spleen. Am J Hematol (1981) 0.92
Erythroid colony growth in congenital hypoplastic anemia. J Clin Invest (1976) 0.92
Recovery of specific activity upon reoxidation of completely reduced polyalanyl rabbit antibody. J Biol Chem (1966) 0.92
A rapid technique for measuring calcium uptake in mitogen-induced T and B lymphocytes. Can J Biochem (1979) 0.92
Isolation and characterization of electrophoretically homogeneous rabbit antihapten antibody populations. I. Separation and properties of homogeneous anti-p-azophenyltrimethyl-ammonium antibodies. J Biol Chem (1971) 0.92
Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med (1986) 0.92
Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res (1999) 0.91
Preparation and studies of 19 F-labeled and enriched 13 C-labeled semisynthetic ribonuclease-S' analogues. J Biol Chem (1973) 0.91
Leukocytes, platelets, and thromboxane A2 in endotoxin-induced lung injury. Surgery (1981) 0.90
In vitro production of an amyloid-like substance from gamma 3 heavy chain disease protein. Immunol Commun (1974) 0.90
Diamond-Blackfan syndrome: evidence against cell-mediated erythropoietic suppression. Blood (1978) 0.90
Genetic locus heterogeneity in Lafora's progressive myoclonus epilepsy. Ann Neurol (1999) 0.90